These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10519380)

  • 1. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
    Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
    Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses.
    Tada M; Iggo RD; Waridel F; Nozaki M; Matsumoto R; Sawamura Y; Shinohe Y; Ikeda J; Abe H
    Mol Carcinog; 1997 Mar; 18(3):171-6. PubMed ID: 9115587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
    Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutants without a functional tetramerisation domain are not oncogenic.
    Chène P; Bechter E
    J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer.
    Hassan NM; Tada M; Hamada J; Kashiwazaki H; Kameyama T; Akhter R; Yamazaki Y; Yano M; Inoue N; Moriuchi T
    Cancer Lett; 2008 Oct; 270(1):108-19. PubMed ID: 18555592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
    Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
    Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas.
    Shahnavaz SA; Regezi JA; Bradley G; Dubé ID; Jordan RC
    J Pathol; 2000 Mar; 190(4):417-22. PubMed ID: 10699989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
    Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
    Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction of chimeric tumor suppressor p53 resistant to the dominant-negative interaction with p53 mutants].
    Almazov VP; Morgunkova AA; Kalinin VN; Kopnin BP; Prasolov VS; Chumakov PM
    Mol Biol (Mosk); 2002; 36(4):664-71. PubMed ID: 12173471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
    Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
    Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro analysis of the dominant negative effect of p53 mutants.
    Chène P
    J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnicity delineates different genetic pathways in malignant glioma.
    Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
    Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
    Inga A; Monti P; Fronza G; Darden T; Resnick MA
    Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 transdominance but no gain of function in mouse brain tumor model.
    Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
    Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
    Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
    Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.